Publication:
Comparative Analysis of Very Reduced vs Full Dose BCG Treatment for High-RiskNon-Muscle Invasive Bladder Cancer:A Contemporary Experience from Chile

Simple item page
dc.contributor.authorGrajales, Valentina
dc.contributor.authorContieri, Roberto
dc.contributor.authorTan, Wei Shen
dc.contributor.authorFlores, Marta
dc.contributor.authorSchultz, Marcela
dc.contributor.authorPinochet, Rodrigo
dc.contributor.authorBustamante, Alberto
dc.contributor.authorKamat, Ashish
dc.contributor.authorMario Fernandez
dc.contributor.authorFernández Arancibia, Mario
dc.date.accessioned2024-06-05T14:45:56Z
dc.date.available2024-06-05T14:45:56Z
dc.date.issued2023
dc.description.abstractBACKGROUND:Adjuvant bacillus Calmette-Gu ́erin (BCG) is recommended for high-risk (HR) non-muscle invasivebladder cancer (NMIBC), but BCG shortages have led to exploration of reduced-dose regimens and shortened maintenancedurations out of necessity, with limited data on treatment efficacy in Latin America.OBJECTIVE:Oncological outcomes of HR-NMIBC patients treated with reduced (RD,1/4th dose) vs full dose (FD) BCGinstillations ofDanish Strain1331 BCG.METHODS:We performed a retrospective study of HR-NMIBC patients treated with BCG between 2003 and 2022 at ourcenter in Santiago Chile. We stratified patients according to either RD (1/4th dose) or FD BCG. Univariate and multivariableCox regression models were used to predict recurrence. Kaplan-Meier method was used to calculate survival estimates.RESULTS:Of a total of 200 patients, 116 (58%) had RD and 84 (42%) FD BCG. Median follow-up was 57 months (IQR:29–100). Patients who received FD BCG had a lower risk of recurrence (HR: 0.41, 95% CI 0.22–0.74) and high-grade(HG)-recurrence (HR: 0.30, 95% CI 0.15–0.61;p= 0.001). More patients in the RD vs FD group progressed to MIBC (10/84vs 2/116;p= 0.18). Additionally, patients were less likely to stop BCG treatment in the RD group compared to the FD groupdue to toxicity (5% vs 11%,p= 0.14).CONCLUSIONS:A 1/4th dose ofDanish Strain1331 BCG treatment was associated with worse recurrence free rate andHG-recurrence rate in our cohort. Patients with RD had lower discontinuation treatment rates due to a reduced toxicity profile.These findings would suggest that RD BCG would compromise oncological outcomes in HR-NMIBC patients.
dc.description.versionPublicada
dc.identifier.citationGrajales, V., Contieri, R., Tan, W. S., Flores, M., Schultz, M., Pinochet, R., Bustamante, A., Kamat, A. M., & Fernández, M. I. (2023). Comparative Analysis of Very Reduced vs Full Dose BCG Treatment for High-Risk Non-Muscle Invasive Bladder Cancer: A Contemporary Experience from Chile. Bladder Cancer, 9(4), 327–334. https://doi.org/10.3233/blc-230047
dc.identifier.doihttps://doi.org/10.3233/BLC-230047
dc.identifier.urihttps://hdl.handle.net/11447/9037
dc.language.isoen
dc.subjectBacillus Calmette-Guerin
dc.subjectBCG. non-muscle-invasive bladder cancer
dc.subjectReduced dose
dc.titleComparative Analysis of Very Reduced vs Full Dose BCG Treatment for High-RiskNon-Muscle Invasive Bladder Cancer:A Contemporary Experience from Chile
dc.typeArticle
dcterms.accessRightsAcceso Abierto
dcterms.sourceBladder Cancer
dspace.entity.typePublication
relation.isAuthorOfPublicationede82ba9-2e79-4469-8218-3f43121e5e01
relation.isAuthorOfPublication.latestForDiscoveryede82ba9-2e79-4469-8218-3f43121e5e01

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Comparative Analysis of Very Reduced vsFull Dose BCG Treatment for High-RiskNon-Muscle Invasive Bladder Cancer A Contemporary Experience from Chile.pdf
Size:
1.82 MB
Format:
Adobe Portable Document Format
Description:
Texto Completo
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
347 B
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Artículos Medicina y Ciencias de la Salud

Implementado por OpenGeek Services